Cargando…

Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma

Disease recurrence is frequent in high-risk neuroblastoma (NBL) patients even after multi-modality aggressive treatment [a combination of chemotherapy, surgical resection, local radiation therapy, autologous stem cell transplantation, and cis-retinoic acid (CRA)]. Recent clinical studies have explor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koehn, Tony A., Trimble, Lori L., Alderson, Kory L., Erbe, Amy K., McDowell, Kimberly A., Grzywacz, Bartosz, Hank, Jacquelyn A., Sondel, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353262/ https://www.ncbi.nlm.nih.gov/pubmed/22623917 http://dx.doi.org/10.3389/fphar.2012.00091

Ejemplares similares

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
por: Alderson, Kory L., et al.
Publicado: (2011)

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
por: Voeller, Julie, et al.
Publicado: (2019)

Immunotherapy of Neuroblastoma: Facts and Hopes
por: Anderson, John, et al.
Publicado: (2022)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma
por: Dhamdhere, Mayura R., et al.
Publicado: (2023)

Human NK Cell Development: One Road or Many?
por: Cichocki, Frank, et al.
Publicado: (2019)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
por: Erbe, Amy K., et al.
Publicado: (2017)

Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy
por: Slattery, Karen, et al.
Publicado: (2022)

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
por: Nguyen, Rosa, et al.
Publicado: (2020)

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
por: Carotta, Sebastian
Publicado: (2016)

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
por: Erbe, Amy K., et al.
Publicado: (2019)

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C
por: Erbe, A K, et al.
Publicado: (2013)

Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy
por: Hoefges, A, et al.
Publicado: (2023)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model
por: Carlson, Peter M, et al.
Publicado: (2021)

Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2(+) Murine Neuroblastoma
por: Bates, Paul D., et al.
Publicado: (2021)

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
por: Carlsten, Mattias, et al.
Publicado: (2015)

Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
por: Tarannum, Mubin, et al.
Publicado: (2022)

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021)

Targets and Antibody Formats for Immunotherapy of Neuroblastoma
por: Park, Jeong A., et al.
Publicado: (2020)

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group
por: Erbe, Amy K, et al.
Publicado: (2023)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

NK cell-based cancer immunotherapy: from basic biology to clinical development
por: Liu, Sizhe, et al.
Publicado: (2021)

Roles of CD4+ T cells as mediators of antitumor immunity
por: Kravtsov, Dmitriy S., et al.
Publicado: (2022)

Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
por: Alfarra, Helmi, et al.
Publicado: (2020)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

Implementing an Assessment Clinic in a Residential PTSD Program
por: McDowell, Joan, et al.
Publicado: (2014)

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
por: Kholodenko, Irina V., et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

Metabolic regulation of NK cell function: implications for immunotherapy
por: Sohn, Hyogon, et al.
Publicado: (2023)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_me7e68ngvgpc669tn1b8jm4uqo